These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 23638195)

  • 1. Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.
    Saljoughian N; Taheri T; Zahedifard F; Taslimi Y; Doustdari F; Bolhassani A; Doroud D; Azizi H; Heidari K; Vasei M; Namvar Asl N; Papadopoulou B; Rafati S
    PLoS Negl Trop Dis; 2013; 7(4):e2174. PubMed ID: 23638195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
    Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
    Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.
    Shahbazi M; Zahedifard F; Taheri T; Taslimi Y; Jamshidi S; Shirian S; Mahdavi N; Hassankhani M; Daneshbod Y; Zarkesh-Esfahani SH; Papadopoulou B; Rafati S
    PLoS One; 2015; 10(7):e0132794. PubMed ID: 26197085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
    Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
    Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum.
    Pirdel L; Farajnia S
    Scand J Immunol; 2017 Jul; 86(1):15-22. PubMed ID: 28426153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis.
    Shahbazi M; Zahedifard F; Saljoughian N; Doroud D; Jamshidi S; Mahdavi N; Shirian S; Daneshbod Y; Hamid Zarkesh-Esfahani S; Papadopoulou B; Rafati S
    Vet Parasitol; 2015 Sep; 212(3-4):130-9. PubMed ID: 26255093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen.
    Zahedifard F; Gholami E; Taheri T; Taslimi Y; Doustdari F; Seyed N; Torkashvand F; Meneses C; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
    PLoS Negl Trop Dis; 2014 Mar; 8(3):e2751. PubMed ID: 24675711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Protective Potency of DNA and Live Vaccines Expressing A2-CPA-CPB
    Taslimi Y; Zahedifard F; Taheri T; Doroud D; Latif Dizaji S; Saljoughian N; Rafati S
    Iran J Parasitol; 2020; 15(3):383-392. PubMed ID: 33082803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice.
    Salari S; Sharifi I; Keyhani AR; Ghasemi Nejad Almani P
    Parasit Vectors; 2020 Aug; 13(1):415. PubMed ID: 32787908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.
    Mazumder S; Maji M; Das A; Ali N
    PLoS One; 2011 Feb; 6(2):e14644. PubMed ID: 21311597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice.
    Rafati S; Zahedifard F; Azari MK; Taslimi Y; Taheri T
    Exp Parasitol; 2008 Mar; 118(3):393-401. PubMed ID: 18093586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.
    Rafati S; Zahedifard F; Nazgouee F
    Vaccine; 2006 Mar; 24(12):2169-75. PubMed ID: 16325969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice.
    Doroud D; Zahedifard F; Vatanara A; Taslimi Y; Vahabpour R; Torkashvand F; Vaziri B; Rouholamini Najafabadi A; Rafati S
    PLoS Negl Trop Dis; 2011 Jul; 5(7):e1236. PubMed ID: 21765963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenicity of
    Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
    Front Immunol; 2018; 9():843. PubMed ID: 29740446
    [No Abstract]   [Full Text] [Related]  

  • 17. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice.
    Iborra S; Soto M; Carrión J; Nieto A; Fernández E; Alonso C; Requena JM
    Infect Immun; 2003 Nov; 71(11):6562-72. PubMed ID: 14573678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK.
    Ramiro MJ; Zárate JJ; Hanke T; Rodriguez D; Rodriguez JR; Esteban M; Lucientes J; Castillo JA; Larraga V
    Vaccine; 2003 Jun; 21(19-20):2474-84. PubMed ID: 12744881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
    Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
    Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis.
    Tewary P; Jain M; Sahani MH; Saxena S; Madhubala R
    J Infect Dis; 2005 Jun; 191(12):2130-7. PubMed ID: 15898000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.